These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 16242075)
21. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244 [TBL] [Abstract][Full Text] [Related]
22. Acetaminophen improves protein translational signaling in aged skeletal muscle. Wu M; Liu H; Fannin J; Katta A; Wang Y; Arvapalli RK; Paturi S; Karkala SK; Rice KM; Blough ER Rejuvenation Res; 2010 Oct; 13(5):571-9. PubMed ID: 20818934 [TBL] [Abstract][Full Text] [Related]
23. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281 [TBL] [Abstract][Full Text] [Related]
24. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Mita MM; Mita A; Rowinsky EK Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096 [TBL] [Abstract][Full Text] [Related]
25. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. Shu L; Zhang X; Houghton PJ J Biol Chem; 2002 May; 277(19):16726-32. PubMed ID: 11875068 [TBL] [Abstract][Full Text] [Related]
33. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
34. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449 [TBL] [Abstract][Full Text] [Related]
35. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515 [TBL] [Abstract][Full Text] [Related]
36. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Hara K; Maruki Y; Long X; Yoshino K; Oshiro N; Hidayat S; Tokunaga C; Avruch J; Yonezawa K Cell; 2002 Jul; 110(2):177-89. PubMed ID: 12150926 [TBL] [Abstract][Full Text] [Related]
37. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. Martin D; Nguyen Q; Molinolo A; Gutkind JS Oncogene; 2014 May; 33(18):2405-12. PubMed ID: 23708663 [TBL] [Abstract][Full Text] [Related]